Integrated Quantitative Investments LLC Makes New $1.15 Million Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Integrated Quantitative Investments LLC bought a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 31,900 shares of the medical device company’s stock, valued at approximately $1,149,000.

Several other large investors have also modified their holdings of the business. Arizona State Retirement System lifted its position in Tandem Diabetes Care by 1.9% in the fourth quarter. Arizona State Retirement System now owns 18,961 shares of the medical device company’s stock valued at $683,000 after buying an additional 362 shares during the last quarter. Assetmark Inc. raised its stake in shares of Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 535 shares during the period. AlphaQuest LLC lifted its holdings in shares of Tandem Diabetes Care by 138.7% in the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock worth $34,000 after acquiring an additional 541 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Tandem Diabetes Care by 4.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,664 shares of the medical device company’s stock worth $664,000 after purchasing an additional 704 shares during the period. Finally, Jones Financial Companies Lllp increased its holdings in Tandem Diabetes Care by 195.8% in the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock valued at $41,000 after purchasing an additional 748 shares during the last quarter.

Insider Buying and Selling

In other news, COO Jean-Claude Kyrillos bought 10,538 shares of the business’s stock in a transaction dated Friday, March 7th. The shares were acquired at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the transaction, the chief operating officer now owns 10,538 shares of the company’s stock, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 2.20% of the stock is owned by company insiders.

Tandem Diabetes Care Stock Down 6.5 %

Shares of NASDAQ:TNDM opened at $17.66 on Friday. The firm has a 50 day simple moving average of $26.75 and a 200-day simple moving average of $32.42. Tandem Diabetes Care, Inc. has a twelve month low of $17.28 and a twelve month high of $53.69. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The company has a market capitalization of $1.17 billion, a PE ratio of -9.15 and a beta of 1.45.

Analyst Upgrades and Downgrades

A number of research analysts have commented on TNDM shares. Wells Fargo & Company restated an “equal weight” rating and set a $22.00 price target (down from $38.00) on shares of Tandem Diabetes Care in a research note on Monday, March 3rd. Sanford C. Bernstein cut Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $35.00 to $25.00 in a report on Friday, February 28th. Citigroup lowered shares of Tandem Diabetes Care from a “buy” rating to a “neutral” rating and cut their price target for the stock from $35.00 to $24.00 in a research note on Tuesday, March 4th. Morgan Stanley lowered shares of Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $45.00 to $22.00 in a research note on Wednesday, March 5th. Finally, Barclays cut their target price on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Eight equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $45.38.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.